Abaloparatide

Source-reported examples · not treatment recommendations

Amount

80 micrograms

Frequency

Once daily

Cycle / observation period

37 administrations is vial arithmetic, not treatment duration

Route / research model

Subcutaneous

The source distinguishes the approved pen from this research vial; they are not equivalent formulations.

Titration & progression

A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.

Compare vial strengths here. A different vial size changes the available material, not the biological dose.

Diluent & formulation

The approved product is supplied as a prepared solution, with no user reconstitution. Its handling instructions do not establish a diluent for a separately supplied research powder.

Read the reconstitution guide →

Selected observations from the cited research. Each finding retains its study population, formulation and limitations.

• Abaloparatide acts at the PTH1 receptor and promotes bone formation. It has been studied in osteoporosis, including fracture outcomes in postmenopausal women and bone-density outcomes in men. The manufactured TYMLOS pen has product-specific indications, dosing and handling instructions. Its evidence does not validate a separately marketed research powder. Important label considerations include orthostatic symptoms, calcium abnormalities and avoidance in people with increased osteosarcoma risk. ^[1]

No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.

Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.

Bibliography checked September 22, 2026: 16 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.

1. TYMLOS prescribing information
2. U.S. FDA, TYMLOS prescribing information (2026) – Official product labeling for the approved abaloparatide injection pen, including 80 mcg once-daily dosing and formulation-specific handling. The pen is not interchangeable with a lyophilized research vial.Regulatory / product information · Listed in reference bibliography.
3. Miller et al., 2016, PMID 27533157 – ACTIVE randomized trial of abaloparatide 80 mcg subcutaneously once daily for 18 months in postmenopausal women with osteoporosis.Further reading · Listed in reference bibliography.
4. Leder et al., 2015, PMID 25393645 – Randomized dose-ranging trial comparing 20, 40, and 80 mcg daily subcutaneous abaloparatide over 24 weeks.Further reading · Listed in reference bibliography.
5. Czerwinski et al., 2022, PMID 36190391 – ATOM randomized trial of 80 mcg daily subcutaneous abaloparatide for 12 months in men with osteoporosis.Further reading · Listed in reference bibliography.
6. Matsumoto et al., 2022, PMID 35977548 – ACTIVE-J randomized trial of 80 mcg daily for 78 weeks in Japanese participants with osteoporosis at high fracture risk.Further reading · Listed in reference bibliography.
7. Miller et al., 2023, PMID 37505256 – Randomized study examining 40 and 80 mcg daily abaloparatide in postmenopausal women.Further reading · Listed in reference bibliography.
8. Moreira et al., 2017, PMID 27826127 – Bone histology and histomorphometry analysis from ACTIVE participants receiving 80 mcg daily.Further reading · Listed in reference bibliography.
9. Bone et al., 2018, PMID 29931216 – ACTIVExtend analysis of sequential abaloparatide followed by alendronate.Further reading · Listed in reference bibliography.
10. Cosman et al., 2019, PMID 31674644 – Post hoc comparison of vertebral fracture outcomes in ACTIVE and ACTIVExtend.Further reading · Listed in reference bibliography.
11. McCloskey et al., 2019, PMID 30719589 – Analysis of fracture outcomes across baseline FRAX risk in ACTIVE.Further reading · Listed in reference bibliography.
12. Bilezikian et al., 2023, PMID 36588166 – Trabecular bone score analysis in participants receiving abaloparatide.Further reading · Listed in reference bibliography.
13. McClung et al., 2018, PMID 29462094 – ACTIVE subgroup analysis in women aged 80 years or older.Further reading · Listed in reference bibliography.
14. Miller et al., 2020, PMID 32513495 – Subgroup analysis of younger postmenopausal women enrolled in ACTIVE.Further reading · Listed in reference bibliography.
15. Watts et al., 2019, PMID 30899994 – Forearm bone-density and wrist-fracture outcomes in ACTIVE.Further reading · Listed in reference bibliography.
16. Doyle et al., 2018, PMID 29167971 – Imaging analysis of trabecular microarchitecture across abaloparatide dose groups.Further reading · Listed in reference bibliography.
17. Leder et al., 2017, PMID 28624872 – Peer-reviewed overview of abaloparatide pharmacology and initial approval.Further reading · Listed in reference bibliography.

Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.